<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-74480</identifier>
<setSpec>0304-5013</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Active management of the third phase of labour plus 400 mg of sublingual misoprostol and 200 mg of rectal misoprostol versus active management only in the prevention of post-partum haemorrhage. A randomised clinical trial</dc:title>
<dc:description xml:lang="en">Objectives: To evaluate the efficacy and safety of 400 mg sublingual misoprostol and 200 mg rectal misoprostol plus active management of the third stage of labour versus active management only to prevent postpartum haemorrhage. Subjects and methods: A total of 1400 women were randomly assigned to receive misoprostol plus active management (group I) or active management only (group II). The variables studied were incidence of postpartum haemorrhage, blood volume lost and need of additional uterotonics. Results: In group I there were 28/702 (4.0%) haemorrhages and in group II 50/698 (7.2%), P=.005; RR =.538; 95% CI for RR (0.335-0.866). In women having postpartum haemorrhage the lost blood volume was 981 ± 309 cc and 888 ± 326 cc. P=.225 in groups I and II, respectively. Additional uterotonics were needed in 33 women in group I (4.7%) vs. 54(7.7%) women in group II (P=.025). Conclusions: The use of sublingual/rectal misoprostol plus active management appears to be useful for the prevention of postpartum haemorrhage (AU)</dc:description>
<dc:creator>Rodríguez Hernández, Juan Manuel</dc:creator>
<dc:creator>Piloto, Mercedes</dc:creator>
<dc:creator>Águila Setién, Sonia</dc:creator>
<dc:creator>Carbonell i Esteve, Josep Lluis</dc:creator>
<dc:creator>Tomási, Giuseppe</dc:creator>
<dc:creator>Sánchez Texidó, Carlos</dc:creator>
<dc:creator>Andreu-Ballester, Juan Carlos</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivos: Evaluar la eficacia y la seguridad de 400 mg de misoprostol por vía sublingual y 200 mg rectal más manejo activo de la tercera fase del parto frente a manejo activo para prevenir la hemorragia posparto. Sujetos y métodos: Se sometió a 1.400 mujeres a recibir el misoprostol más manejo activo (grupo I) o manejo activo (grupo II). Las variables medidas fueron la incidencia de hemorragia posparto, el volumen de sangre perdido y el uso de uterotónicos adicionales. Resultados: En el grupo I hubo 28/702 (4,0%) hemorragias y en el grupo II 50/698 (7,2%), p = 0,005; riesgo relativo (RR) = 0,538; intervalo de confianza (IC) del 95% para RR (0,335-0,866). En mujeres con hemorragia posparto, el volumen de sangre perdida fue 981 ± 309 cc y 888 ± 326 cc, p = 0,225 en los grupos I y II, respectivamente. Necesitaron uterotónicos adicionales 33 (4,7%) frente a 54 (7,7% mujeres, p = 0,025 en los grupos I y II, respectivamente). Conclusiones: Se podría recomendar la administración de misoprostol por vía sublingual/rectal junto al manejo activo para prevenir la hemorragia posparto (AU)</dc:description>
<dc:source>Prog. obstet. ginecol. (Ed. impr.);52(10): 543-551, oct. 2009. tab</dc:source>
<dc:identifier>ibc-74480</dc:identifier>
<dc:title xml:lang="es">Manejo activo de la tercera fase del parto más 400 mg de misoprostol sublingual y 200 mg de misoprostol rectal frente a manejo activo solo en la prevención de la hemorragia posparto. Ensayo clínico aleatorizado</dc:title>
<dc:subject>^d29646</dc:subject>
<dc:subject>^d6625^s22054</dc:subject>
<dc:subject>^d6625^s22032</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d28570^s22048</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d29962^s22073</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d22827</dc:subject>
<dc:subject>^d29962^s22000</dc:subject>
<dc:subject>^d29962^s22044</dc:subject>
<dc:subject>^d29962^s22078</dc:subject>
<dc:subject>^d29962^s22079</dc:subject>
<dc:subject>^d6625^s22080</dc:subject>
<dc:subject>^d19058</dc:subject>
<dc:type>article</dc:type>
<dc:date>200910</dc:date>
</metadata>
</record>
</ibecs-document>
